ABCL
AbCellera Biologics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ABCL Profile
Abcellera Biologics Inc.
A Canadian provider of drug discovery platform that designed to develop next-generation antibody therapies
Biological Technology
11/08/2012
12/11/2020
NASDAQ Stock Exchange
596
12-31
Common stock
150 W 4th Avenue, Vancouver, BC V5Y 1G6
--
AbCellera Biologics Inc., was incorporated and commenced business activities on November 8, 2012 under the British Columbia Business Companies Act. The company is engaged in the business of combining a variety of complex technologies in its medical research and development to discover antibody drugs faster, cheaper and more efficiently. Since its inception, the company has been committed to R&D activities to support its current partner projects and future platform development efforts.